What is the drug Sibbonti (denosumab) used for?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Sibbonti (Denosumab) - Primary Indications

Sibbonti is denosumab, a fully humanized monoclonal antibody used primarily for the treatment of osteoporosis in postmenopausal women at high risk for fractures, and for preventing skeletal-related events in patients with bone metastases from solid tumors. 1, 2

Primary Approved Uses

1. Osteoporosis Treatment

Denosumab is recommended as an alternative initial treatment for postmenopausal women with osteoporosis who are at high risk for osteoporotic fractures. 1 The standard dosing is 60 mg subcutaneously every 6 months. 1, 2

Key efficacy data:

  • 68% reduction in vertebral fractures (HR 0.32; 95% CI 0.26-0.40)
  • 39% reduction in hip fractures (HR 0.61; 95% CI 0.37-0.98)
  • 19% reduction in nonvertebral fractures (HR 0.81; 95% CI 0.69-0.95) 1

The FREEDOM trial and its 10-year extension demonstrated sustained fracture reduction with continued low annual rates of new vertebral fractures (0.9-1.86% per year) and hip fractures (0-0.61% per year) through year 10. 1

2. Bone Metastases Management

Denosumab (120 mg subcutaneously every 4 weeks) is used to prevent skeletal-related events in patients with bone metastases from solid tumors, particularly breast and prostate cancer. 3 In breast cancer patients with bone metastases, denosumab was statistically superior to zoledronate in delaying first and subsequent skeletal-related events. 3

3. Additional Indications

  • Glucocorticoid-induced osteoporosis 4
  • Prevention of bone loss in men receiving androgen deprivation therapy for prostate cancer 4
  • Prevention of bone loss in women receiving aromatase inhibitor therapy for breast cancer 4

Critical Safety Considerations

Dosing Adherence is Non-Negotiable

Drug holidays or treatment interruptions are NOT recommended with denosumab. 1 The drug's effects on bone remodeling reverse after 6 months if not taken on schedule. 1 Delayed or missed doses lead to:

  • Rapid rebound in bone turnover (bone turnover markers increase above baseline within 3-6 months) 1
  • BMD declines to pretreatment levels within 18-24 months 1
  • Increased risk of multiple vertebral fractures 1, 2

Discontinuation Protocol

If denosumab must be stopped, immediate transition to another antiresorptive therapy (bisphosphonate, hormone therapy, or SERM) is mandatory to prevent rebound bone loss and vertebral fractures. 1

Key Contraindications and Precautions

Hypocalcemia:

  • Denosumab is contraindicated in patients with hypocalcemia 2
  • Ensure adequate calcium and vitamin D supplementation before initiating treatment 1, 2
  • High-risk patients require monitoring: Those with chronic kidney disease (eGFR <30 mL/min), malabsorption, or hypoparathyroidism 1
  • Monitor serum calcium, magnesium, and phosphorus within 14 days of injection in at-risk patients 1

Chronic Kidney Disease:

  • Unlike bisphosphonates, denosumab can be used in patients with severe renal impairment (eGFR <35 mL/min) 1
  • However, these patients face significantly higher hypocalcemia risk (14-25% in small studies vs 0.05% in general population) 1

Osteonecrosis of the Jaw (ONJ):

  • Risk increases with invasive dental procedures, particularly tooth extractions 5, 6
  • Preventive strategy: Complete necessary dental work and optimize oral health BEFORE starting denosumab 5, 6
  • If dental extraction is needed during treatment, coordinate timing with dosing schedule during periods of waning drug effect 6

Atypical Femoral Fractures (AFF):

  • Rare complication associated with long-term use 1
  • Benefits strongly outweigh risks for up to 5-10 years in high-risk patients 1

Treatment Duration and Monitoring

Reassess fracture risk after 5-10 years of treatment. 1 Patients who remain at high risk should either:

  • Continue denosumab, or
  • Transition to other osteoporosis therapies 1

Real-world data through 10 years shows continued BMD gains (+12.9% total hip, +16.3% lumbar spine) with sustained low fracture rates. 7 Prior bisphosphonate use does not affect long-term BMD response. 7

Clinical Advantages

  • Rapid onset: Marked suppression of bone turnover within the first week 1
  • Superior adherence: 87-95% persistence at 12 months vs ~30% with oral bisphosphonates 1
  • Patient preference: Significantly preferred over oral bisphosphonates in head-to-head studies 1
  • Usable in renal impairment: Unlike bisphosphonates, can be administered with eGFR <35 mL/min (with appropriate calcium monitoring) 1

References

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.